+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation



In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation



Journal of Clinical Oncology 14(10): 2791-2802



Purpose: To evaluate the following prospectively in poor-risk neuroblastoma (NBL) patients: (1) the feasibility and efficacy of in vivo purging of bone marrow; and (2) the outcome after autologous bone marrow transplantation (ABMT) when immunologically tumor-free, unpurged autografts were used. Patients and Methods: Twenty-three children with poor-risk NBL were evaluated during induction chemotherapy by repeat bone marrow examinations, including aspirate, biopsy, and an immunofluorescence method using the anti-GD2 monoclonal antibody 3A7. Nineteen patients completed the program with surgery with or without local irradiation followed by ABMT. Results: Autologous bone marrow grafts, both immunologically and cytologically clean, were obtained and used in 19 of 23 children. The overall 4-year disease-free survival of the 19 grafted children was 53%, with a toxic death rate of 16% and a posttransplant relapse rate of 37%. According to the in vivo purging efficacy of the 18 children with initial marrow disease, the following three groups were formed: patients with (1) perfect in vivo purging (n = 5); (2) eventually successful in vivo purging (n = 8); and (3) unsuccessful in vivo purging (n = 5). The 4-year DFS was 100%, 67%, and 0%, respectively (P lt 0.001). The five patients with unsuccessful in vivo purging failed because of resistant/progressive bulky disease. Conclusion: In patients with poor-risk NBL, in vivo purging of bone marrow by conventional chemotherapy is feasible, can be monitored, and the purging efficacy during the first 3 months after diagnosis is a strong prognostic factor reflecting tumor responsiveness to therapy. Autografting with immunologically clean, unpurged marrows gives a DFS well comparable to previous studies using ex vivo purging.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008842727

Download citation: RISBibTeXText

PMID: 8874341

DOI: 10.1200/jco.1996.14.10.2791


Related references

Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: Clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement. Bone Marrow Transplantation 24(6): 621-627, Sept 2, 1999

Autologous bone marrow transplantation in high risk remission b lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies ba 1 cd24 ba 2 cd9 and ba 3 cd10 plus complement and 4 hydroperoxycyclophosphamide for ex vivo bone marrow purging. Blood 79(4): 1094-1104, 1992

Application of serum-free liquid bone marrow cultures to bone marrow purging for autologous bone marrow transplantation in acute lymphoblastic leukemia. Nouvelle Revue Francaise d'Hematologie 32(5): 353-355, 1990

Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT). Leukemia 5(10): 896-904, 1991

Marrow purging for autologous bone marrow transplantation and its role in acute myelocytic leukemia. European Cooperative Group for Bone Marrow Transplantation. (EBMT). Leukemia 6 Suppl 2: 96-101, 1992

Bone marrow resident memory T cells are not affected by both previous chemotherapy and marrow purging in patients given autologous bone marrow transplantation. Blood 96(11 Part 1): 789a, November 16, 2000

Marrow purging in autologous bone marrow transplantation for t lineage acute lymphoblastic leukemia efficacy of ex vivo treatment with immunotoxins and 4 hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells. Blood 69(1): 361-366, 1987

In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation. Experimental Hematology 21(2): 311-318, 1993

Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group. Blood 77(7): 1593-1598, 1991

In vivo and in vitro purging of bone marrow in autologous bone marrow transplantation. Bone Marrow Transplantation 2(SUPPL 2): 123, 1987

Autologous bone marrow transplantation using ex-vivo etoposide purged marrow in patients with poor risk lymphomas and acute leukemias. Blood 82(10 SUPPL 1): 629A, 1993

Immunotoxins for ex vivo marrow purging in autologous bone marrow transplantation for acute nonlymphocytic leukemia. Transplantation 46(2): 240-245, 1988

Immunological changes induced by ex vivo marrow purging with high doses mafosfamide for autologous bone marrow transplantation. Experimental Hematology 19(6): 560, 1991

An innovative approach to bone marrow collection and transplantation in a patient with beta-thalassemia major: marrow collection using a perfusion method followed by intra-bone marrow injection of collected bone marrow cells. International Journal of Hematology 85(1): 73-77, 2007

Marrow purging in autologous bone marrow transplantation for children with acute leukemia. Blood 98(11 Part 2): 342b, November 16, 2001